Skip to main content
. Author manuscript; available in PMC: 2023 Jul 11.
Published in final edited form as: Sci Transl Med. 2023 Jan 11;15(678):eadd8469. doi: 10.1126/scitranslmed.add8469

Figure 5. SCLC AAbs target citrullinated TFRC.

Figure 5.

(A) Shown are immunoblots from H82 or H69 whole cell lysates (WCL) probed with TFRC or citruilline antibodies (N=3). GAPDH was used for a loading control. (B) Shown are immunoblots from 3T3 or H82 WCL and H82 lysates immunoprecipitated with TFRC, citrulline (CIT), or isotype control antibody (CON) and probed with anti-TFRC or anti-citrulline antibodies (N=3). (C) The ratio of IgG from SCLC patient plasma bound to citrullinated (Cit) compared to wild type (WT) peptides was measured by ELISA (n=8). (D) IgG from 10 patients with SCLC (case) and 10 controls (ctrl) captured in complex with antigen (AAb-TAA) by anti-TFRC antibody, free from antigen (AAb) by TFRC recombinant protein, or by cit/WT peptides were quantified by ELISA. An anti-TFRC antibody was used a positive control (pos ctrl) for TFRC recombinant protein. Data are presented as individual data points, the horizonal bar as mean ± SEM. *p<0.05 and **p<0.005 by paired sample t tests.